[8-K] Werewolf Therapeutics, Inc. Reports Material Event

Rhea-AI Filing Summary

Werewolf Therapeutics announced that it furnished a press release reporting its financial results for the quarter ended June 30, 2025, and that the press release is provided as Exhibit 99.1. The company also made an updated corporate investor presentation publicly available and furnished it as Exhibit 99.2. The filing specifies that these items are being furnished rather than filed under the Exchange Act and includes a standard cautionary note describing forward-looking statements and associated development, regulatory, and financing risks.

The 8-K does not include the financial figures within its text but notifies investors where the results and presentation are available as exhibits for review.

Positive

• Press release furnished as Exhibit 99.1 announcing financial results for the quarter ended June 30, 2025
• Updated investor presentation furnished as Exhibit 99.2 and made publicly available on the company website

Negative

• None.

Insights

Financial Analyst

TL;DR: Routine disclosure—company furnished Q2 results and an updated investor presentation; no financial details appear in the filing itself.

The filing serves to notify the market that Werewolf Therapeutics has made its quarterly results public via a press release and updated its investor presentation, both furnished as exhibits. Because the 8-K itself contains no earnings figures or guidance, there is no new quantitative information for valuation or modeling in this document alone. The inclusion of a standard forward-looking statements caution is routine and reiterates known development, regulatory, and financing risks identified elsewhere in SEC filings.

Corporate Governance Expert

TL;DR: Disclosure practices are standard—furnishing exhibits and reiterating forward-looking caution is consistent with Regulation FD and SEC norms.

The company complied with disclosure norms by furnishing a press release and an updated investor presentation as exhibits rather than filing them, and explicitly stated they are not "filed" under Section 18. This approach preserves the company’s ability to update materials while meeting public disclosure expectations. No governance or control changes, officer departures, or material contracts are reported in this item.

0001785530FALSE00017855302025-08-142025-08-14

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

______________________

FORM 8-K

______________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 14, 2025

___________________________________________

WEREWOLF THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

___________________________________________

Delaware			001-40366			82-3523180
(State or Other Jurisdiction			(Commission			(IRS Employer
of Incorporation)			File Number)			Identification No.)

200 Talcott Ave, 2nd Floor
Watertown, Massachusetts			02472
(Address of Principal Executive Offices)			(Zip Code)

Registrant’s telephone number, including area code: (617) 952-0555

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.0001 par value per share

HOWL

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Item 2.02. Results of Operations and Financial Condition.

On August 14, 2025, Werewolf Therapeutics, Inc., a Delaware corporation (the “Company”), issued a press release announcing financial results for the quarter ended June 30, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information contained in Item 2.02 in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 7.01. Regulation FD Disclosure.

On August 14, 2025, the Company made publicly available on its website an updated corporate presentation. A copy of the presentation is furnished as Exhibit 99.2 hereto and is incorporated herein by reference.

The information furnished under this Item 7.01, including Exhibit 99.2, shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

Exhibit No.						Description
99.1						Press release issued by the Company on August 14, 2025
99.2						Investor Presentation, dated August 2025
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

Cautionary Note Regarding Forward-Looking Statements

Any statements in this Current Report on Form 8-K about the Company’s future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to substantial risks and uncertainties and actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include statements regarding the Company’s strategy, future operations, prospects, plans, objectives of management, the projection of the cash runway, the expected timeline for the preclinical and clinical development of product candidates and the availability of data from such preclinical and clinical development, the timing of anticipated regulatory engagement, the potential activity and efficacy of product candidates in preclinical studies and clinical trials, and the anticipated safety profile of product candidates. The words “aim,” “anticipate,” “approach,” “believe,” “contemplate,” “continue,” “could,” “design,” “designed to,” “engineered,” “estimate,” “expect,” “goal,” “intend,” “may,” “might,” “objective,” “ongoing,” “plan,” “potential,” “predict,” “project,” “promise,” “should,” “target,” “will,” or “would,” or the negative of these terms, or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: uncertainties inherent in the development of product candidates, including the conduct of research activities and the initiation and completion of preclinical studies and clinical trials; uncertainties as to the availability and timing of results from preclinical studies and clinical trials; the timing of and the Company’s ability to submit and obtain regulatory approval for investigational new drug applications; whether results from preclinical studies will be predictive of the results of later preclinical studies and clinical trials; whether preliminary or interim data from a clinical trial will be predictive of the future results of the trial and future clinical trials; the Company’s ability to manage cash resources and obtain additional cash resources to fund the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements; as well as the risks and uncertainties identified in the “Risk Factors” section of the Company’s most recent Form 10-Q filed with the Securities and Exchange Commission (“SEC”), and in subsequent filings the Company may make with the SEC. In addition, the forward-looking statements included in this Current Report on Form 8-K represent the Company’s views as of the date of this Current Report on Form 8-K. The Company anticipates that subsequent events and developments will cause its views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements

should not be relied upon as representing the Company’s views as of any date subsequent to the date of this Current Report on Form 8-K.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			WEREWOLF THERAPEUTICS, INC.
Date: August 14, 2025			By:			/s/ Timothy W. Trost
						Timothy W. Trost
						Chief Financial Officer and Treasurer

FAQ

What did Werewolf Therapeutics (HOWL) disclose in this 8-K?

The company furnished a press release with financial results for the quarter ended June 30, 2025 (Exhibit 99.1) and an updated investor presentation (Exhibit 99.2).

Does this 8-K include the financial results numbers for HOWL?

No. The 8-K states the press release containing the financial results is furnished as Exhibit 99.1; the filing itself does not reproduce the financial figures.

Where can investors find the detailed results and presentation for HOWL?

Investors can review the press release (Exhibit 99.1) and the investor presentation (Exhibit 99.2), both furnished with the 8-K and made publicly available by the company.

Did Werewolf Therapeutics (HOWL) make any material corporate changes in this filing?

No material corporate changes were disclosed. The filing reports the furnishing of a press release and presentation and includes a standard forward-looking statements caution.

Does the filing include a forward-looking statements disclaimer for HOWL?

Yes. The 8-K contains a cautionary note identifying forward-looking statements and lists development, regulatory, and financing risks referenced in the company's SEC filings.